

CONTENTS

Section No.	Title	Page No.
	List of Abbreviations	i
	List of Tables	ii
	List of Figures	vii
1.0	INTRODUCTION	1-7
1.1	Aims and Objectives	4
1.2	Plan of Work	5
	References	6
2.0	LITERATURE REVIEW	8-83
2.1	Leukaemia	8
2.1.1	Causes of Leukaemia	8
2.1.2	Symptoms	8
2.1.3	Types of leukaemia	9
2.1.4	Treatment options for leukemia by type	10
2.1.5	Drawbacks associated with conventional therapy	16
2.2	Nanoparticulate Drug Delivery Systems For Cancer Drugs	17
2.2.1	Drawbacks associated with conventional Nanoparticles	19
2.2.2	Sterically Stabilized Nanoparticles	19
2.3	PLGA Based Nanoparticulate Drug Delivery Systems	21
2.3.1	Methods for Preparation of PLGA Nanoparticles	24
2.3.2	Characterization of Nanoparticles	28
2.3.3	Drug Loading and Encapsulation efficiency	29
2.3.4	Drug release studies from PLGA Nanoparticles	31
2.3.5	Mechanism of drug release from PLGA NP	35
2.4	Factorial Design	37
2.5	Cell Line Studies	39
2.5.1	Evaluation of Cellular Uptake by Flow Cytometry and Confocal Microscopy	39
2.5.2	Cytotoxicity Assay	40
2.6	Radiolabeling Studies	41
2.6.1	Technetium-99m	41

2.6.2	Radiolabeling studies of Drugs and Drug loaded Nanoparticles	44
2.7	Drug Profile	46
2.7.1	Etoposide	46
2.7.2	Cytarabine	52
2.8	PROFILE OF POLYMERS	60
2.8.1	Poly(D,L-lactide-co-glycolide) PLGA	60
2.8.2	Pluronic F 68	64
2.9	PROFILE OF THE CELL LINES	67
2.9.1	DU 145 Cells	67
2.9.2	L1210 Cells	69
	References	71
3.0	ANALYTICAL METHODS	84-100
3.1	Materials	84
3.2	Estimation of Etoposide by UV Spectrophotometry	84
3.2.1	Calibration curve of Etoposide in Methanolic Phosphate Buffer Saline (3:7)	84
3.2.2	Calibration curve of Etoposide in Chloroform	85
3.2.3	Estimation of Etoposide from PLGA, PLGA-mPEG or PLGA-PLURONIC nanoparticles	85
3.2.4	Validation parameters	85
3.2.4.1	Accuracy and Precision	85
3.2.4.2	Linearity	86
3.2.4.3	Stability and selectivity	86
3.2.5	Results and Discussion	87
3.3.	Cytarabine Analytical Method	95
3.3.1	Calibration curve of Cytarabine in Phosphate Buffer Saline(PBS) pH 7.4	95
3.3.2	Estimation of Cytarabine in PLGA and PLGA-MPEG NP	95
3.3.3	Validation parameters	95
3.3.4	Results and Discussion	96
	References	100
4.0	FORMULATION DEVELOPMENT AND EVALUATION OF ETOPOSIDE LOADED PLGA BASED NANOPARTICLES	101-182
4.1	Materials	101
4A	ETOPOSIDE LOADED PLGA NANOPARTICLES	102

4.2.1	Preparation of Blank PLGA Nanoparticles	102
4.2.2	Formulation development of Etoposide loaded PLGA Nanoparticles	102
4.3	Optimization by factorial design	103
4.4	Evaluation of Nanoparticles	106
4.4.1	Particle Size and Polydispersity index	106
4.4.2	Entrapment Efficiency	106
4.4.3	Surface charge	106
4.4.4	DSC Thermograms	106
4.4.5	XRD Studies	107
4.4.6	Scanning Electron Microscopy	107
4.4.7	In Vitro Drug Release Studies	107
4.4.8	Mathematical modeling of drug release kinetics	107
4.4.9	Stability studies	108
4.5	Results and Discussion	109
4.5.1	Formulation Optimization of Blank PLGA NP	109
4.5.2	Optimization using Factorial Design for formulation of Etoposide loaded PLGA NP	116
4.5.2.1	Entrapment Efficiency	117
4.5.2.2	Mean Particle Size	121
4.5.2.3	Check point analysis	125
4.5.3	Zeta potential	127
4.5.4	Optimization of cryoprotectant	130
4.5.5	DSC studies	132
4.5.6	XRD studies	133
4.5.7	SEM studies	134
4.5.8	Drug Release studies	135
4.5.9	Stability studies	140
4B	FORMULATION DEVELOPMENT AND EVALUATION OF ETOPOSIDE LOADED PLGA-MPEG AND PLGA-PLURONIC NANOPARTICLES	145
4.6	Introduction	145
4.7	Synthesis of PLGA-mPEG copolymer	146
4.8	Synthesis of PLGA-PLURONIC copolymer	146
4.9	¹ H-NMR and Fourier Transform - Infrared Spectrum	146
4.10	Preparation of Etoposide loaded PLGA-mPEG nanoparticles and	147

	PLGA-Pluronic nanoparticles	
4.11	Evaluation of Nanoparticles	147
4.12	Stability study of Nanoparticles	147
4.13	Results and Discussion	148
4.13.1	¹ H-NMR Spectrum	148
4.13.2	FT-IR Spectrum	149
4.13.3	Optimization of Etoposide Loaded PLGA-MPEG NP Using Factorial Design	151
4.13.3.1	Response -Mean particle size (MPS)	151
4.13.3.2	Response - %EE PLGA-MPEG NP	156
4.13.4	Zeta potential of PLGA-mPEG NP	161
4.13.5	Optimization of Etoposide Loaded PLGA-PLURONIC NP	164
4.13.5.1	Zeta potential of PLGA-PLURONIC NP	166
4.13.6	Lyophilization and optimization of cryoprotectant	167
4.13.7	XRD studies	168
4.13.8	SEM studies	169
4.13.9	Drug Release studies	170
4.13.10	Stability studies	174
	References	179
5.0	FORMULATION DEVELOPMENT AND EVALUATION OF CYTARABINE LOADED PLGA AND PLGA-MPEG NANOPARTICLES	183-225
5.1	Materials	183
5.2	Formulation development of Cytarabine loaded PLGA and PLGA-mPEG Nanoparticles	183
5.3	Evaluation of Nanoparticles	185
5.4	Results and Discussions	187
5.4.1	Choice of co-solvent	187
5.4.2	Optimization of volume of co-solvent and non solvent by factorial design for formulation of Cytarabine loaded PLGA NP	188
5.4.3	Optimization of drug: polymer ratio (for polymer concentration) and stirring time by using Factorial Design for formulation of Cyt-PLGA NP	193
5.4.3.1	Response-Mean Particle Size	194
5.4.3.2	Response-Entrapment Efficiency	199
5.4.4	Optimization using 3 ² Factorial Design for formulation of Cyt-PLGA-MPEG NP	204

5.4.4.1	Response-Mean Particle Size	205
5.4.4.2	Response: Entrapment Efficiency	209
5.4.5	Lyophilization and optimization of cryoprotectant	213
5.4.6	SEM studies	215
5.4.7	X-ray powder diffraction studies	216
5.4.8	DSC studies	216
5.4.9	In vitro drug release	218
5.4.10	Stability studies	222
	References	225
6.0	CYTOTOTOXICITY AND CELLULAR UPTAKE STUDIES	226-261
6.1	Introduction	226
6.2	Materials	227
6.3	Maintenance and subculturing of Cell lines	228
6A	CYTOTOTOXICITY STUDIES	229
6.4	Cytotoxicity assay	229
6.5	Results and discussions of cytotoxicity studies of etoposide and etoposide loaded PLGA nanoparticles	230
6.5.1	Long term cytotoxicity study	235
6.5.2	Cytotoxicity study of the polymers used	237
6.6	Results and Discussions: cytotoxicity studies on cytarabine and cytarabine Loaded PLGA Nanoparticles	238
6B	CELLULAR UPTAKE STUDIES	243
6.7	Introduction	243
6.8	Preparation of 6-coumarin loaded nanoparticles	244
6.9	Cell uptake efficiency	244
6.10	Confocal microscopy	245
6.11	Flow Cytometry	245
6.12	Statistical Methods	245
6.13	Results and Discussion	246
6.13.1	Cellular uptake efficiency	246
6.13.2	Confocal microscopy	249
6.13.3	Flow Cytometry	257
	References	260

7.0	RADIOLABELING, BIODISTRIBUTION AND BLOOD CLEARANCE STUDIES	262-306
7.1	Introduction	262
7.2	Materials	264
7A	RADIOLABELING STUDIES	265
7.3	Radiolabeling of formulations	265
7.4	Labeling efficiency and colloid formation	265
7.5	Stability of the ^{99m}Tc Labeled Complexes	265
7.6	Results and discussion of radiolabeling studies	266
7.6.1	Etoposide and etoposide loaded nanoparticles	266
7.6.2	Cytarabine and cytarabine loaded nanoparticles	270
7B	BIODISTRIBUTION STUDIES	273
7.7	Introduction	273
7.8	Biodistribution studies	275
7.9	Results and discussions for Biodistribution studies	276
7.9.1	Etoposide and etoposide loaded nanoparticles	276
7.9.1.1	Biodistribution Studies of ^{99m}Tc -Eto-PLGA NP ₁₀₅ and ^{99m}Tc - Eto-PLGA NP ₁₆₀	276
7.9.1.2	Biodistribution Studies of ^{99m}Tc -Eto-PLGA-PLU NP and ^{99m}Tc - Eto-PLGA-mPEG NP	283
7.9.2	Cytarabine and Cytarabine loaded nanoparticles	290
7C	BLOOD CLEARANCE STUDIES	299
7.10	Blood Clearance studies in Rats	299
7.11	Results and Discussion	299
7.11.1	Blood Clearance of Etoposide and Etoposide loaded Nanoparticles	299
7.11.2	Blood Clearance of cytarabine and cytarabine loaded Nanoparticles	302
	References	304
8.0	SUMMARY AND CONCLUSION	307-322
8.1	Summary	307
8.2	Conclusion	321
